Tune Therapeutics, a Durham biotechnology startup co-founded by a Duke professor, announced the completion of its Series B fundraising round on Jan. 12, in which it raised $175 million to support ...
Regeneron, San Diego-based biotech company Illumina and 17 health systems invested in the $320 million round. Regeneron ...
Tune Therapeutics shared a major milestone this week as the Durham startup raised $175 million to fund its first clinical trial. Born at Duke University, Tune has developed a new epigenome editor ...
The LIGHTHOUSE study is a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial evaluating the safety and tolerability of ATSN-201 in male patients ages six and older with a ...
She has held research leadership roles at organizations including Juno Therapeutics, Celgene, and Lyell Immunopharma and is currently the head of research at Tune Therapeutics. She brings strong ...